TYK Medicines

China

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
Phase 3
Next date
TYK-00540, Phase 1/2 trial completes
Drugs
4
in active trials · 8 in all
Trials
8 active
17 since 2021

Drugs4

DrugHow it worksPartnerStageNext dateDetails
EGFR inhibitor
Phase 3 1 Dec 2027Phase 2 trial completes
—
Phase 1/2 Nov 2026soonPhase 1/2 trial completes
—
Phase 1/2 Jan 2028Phase 1/2 trial completes
—
Phase 1/2 —

About

No active trial
Rifampicin, TY-1091, TY-2136b, TY-2699a
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021

Follow TYK Medicines

Following is part of Solo: you see every change to TYK Medicines the day it happens.

Solo

$49a month

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in